,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
[]
t-dxd has a higher incidence of nausea, vomiting and alopecia, this is related to the higher payload that also explains the massive clinical impact of this drug, stable grade 3 ild (0.8%). a small price for a practice changing adc. #asco22
Esposo, papá, Médico